Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Is there a role for combination therapy in CML?

Massimo Breccia • 4 Sep 2024
SOHO 2024
Chronic Myeloid Leukemia Leukemia Dasatinib Interferon Venetoclax

In this video, Massimo Breccia, MD, Sapienza University, Rome, Italy, briefly discusses the possibility of using combination therapies in the treatment of first-line chronic-phase chronic myeloid leukemia (CML), highlighting that combinations of agents that have previously been tested in trials have failed to demonstrate the desired efficacy. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Massimo Breccia

Mechanisms of resistance to the TKI asciminib in CML 1:16
Mechanisms of resistance to the TKI asciminib in CML
Massimo Breccia • 4 Sep 2024
Treatment-free remission after second-generation TKI treatment in CML 1:01
Treatment-free remission after second-generation TKI treatment in CML
Massimo Breccia • 4 Sep 2024
The diagnosis and management of MDS/MPN with neutrophilia (atypical CML) 1:15
The diagnosis and management of MDS/MPN with neutrophilia (atypical CML)
Massimo Breccia • 4 Sep 2024
Long-term follow-up from the OITI trial: ponatinib in patients with CML in Italy 1:34
Long-term follow-up from the OITI trial: ponatinib in patients with CML in Italy
Massimo Breccia • 13 Jun 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals